Benefits of Hyaluronic Acid for Dogs – Gut-Joint Axis Support
Summary
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found in high concentrations in synovial fluid and articular cartilage, where it serves as the primary lubricant and shock absorber in healthy joints. As osteoarthritis progresses, both the concentration and molecular weight of HA in affected joints decline significantly, compromising lubrication, increasing friction, and accelerating cartilage degradation.¹ While intra-articular HA injections have been used in veterinary medicine for decades, emerging canine research now demonstrates that oral HA supplementation can significantly improve osteoarthritis biomarkers in dogs — increasing synovial fluid HA concentrations and reducing inflammatory markers.² HA is generally well tolerated in dogs, with no reported adverse effects from oral supplementation in clinical studies.² Bonza includes hyaluronic acid at 5mg per chewy in Bounce Bioactive Bites as part of a synergistic joint-support formulation designed to restore lubrication, reduce inflammation, and protect cartilage integrity.
Key Takeaways
- Hyaluronic acid is the principal component of synovial fluid responsible for joint lubrication and shock absorption, and its concentration declines significantly as osteoarthritis progresses in dogs.¹
- A prospective, randomised, double-blind canine clinical study demonstrated that oral HA supplementation significantly increased synovial fluid HA concentrations (p = 0.0016) and reduced the inflammatory biomarker paraoxonase-1 (p = 0.011) after 10 weeks.²
- Oral HA is absorbed through a gut-microbiota-dependent mechanism: Bacteroides species in the gut degrade HA into absorbable oligosaccharides, establishing a direct link between gut health and joint-support efficacy.³
- High-molecular-weight HA inhibits the production of matrix metalloproteinases (MMPs) and pro-inflammatory cytokines, protecting cartilage from enzymatic degradation while reducing pain signalling through direct interaction with joint nociceptors.⁴
- When combined with glucosamine, chondroitin, and anti-inflammatory botanicals — as in Bonza Bounce — HA contributes to a multi-mechanism approach that addresses lubrication, structural repair, and inflammation simultaneously.
In this guide:
- What Is Hyaluronic Acid?
- Bioactive Compounds and How They Work
- Health Benefits for Dogs
- Hyaluronic Acid and Gut Health
- Why Bonza Includes Hyaluronic Acid
- Safety Profile
- How to Give Hyaluronic Acid to Your Dog
- Dosage Guidelines
- Practical Considerations
- Frequently Asked Questions
- Related Reading
- References
- Editorial Information
- About the Author
What Is Hyaluronic Acid?
Hyaluronic acid — also known as hyaluronan or hyaluronate — is a non-sulphated glycosaminoglycan composed of repeating disaccharide units of D-glucuronic acid and N-acetylglucosamine.⁴ It is one of the most abundant components of the extracellular matrix in mammals and is synthesised by chondrocytes, synoviocytes, and fibroblasts throughout the body.
Within the joint, HA is the primary molecule responsible for the viscoelastic properties of synovial fluid. It generates an environment that facilitates cell migration and proliferation while conferring lubrication and shock-absorbing capacity to articular surfaces.² In a healthy canine joint, HA exists predominantly as a high-molecular-weight polymer (typically 1,000–8,000 kDa), and it is this high-molecular-weight form that provides the optimal viscous and elastic properties required for smooth, pain-free movement.⁴
HA was first identified in 1934 by Karl Meyer and John Palmer in the vitreous body of bovine eyes.⁴ The first therapeutic injections of HA in animal joints were performed on racehorses for traumatic arthritis, and this approach subsequently became established in both equine and canine veterinary medicine.⁴ More recently, research into oral HA supplementation has opened new possibilities for non-invasive joint support, with canine clinical studies demonstrating measurable improvements in osteoarthritis biomarkers.²
Beyond the joints, HA is distributed throughout virtually every tissue in the body — approximately half of total body HA is found in the skin, with significant concentrations also present in the eyes, heart valves, and umbilical cord.⁴ In the context of joint health, however, it is the synovial fluid and cartilage matrix where HA performs its most critical functions.
Bioactive Compounds and How They Work
Unlike many botanical supplements that contain multiple distinct bioactive compounds, hyaluronic acid is itself the bioactive molecule. Its therapeutic effects are determined primarily by its molecular weight, which dictates both its physical properties within the joint and its biological signalling activity.
High-molecular-weight HA (HMW-HA; >500 kDa) is the form most closely resembling the naturally occurring HA in healthy joints. HMW-HA is responsible for the viscous and elastic properties of synovial fluid, providing both lubrication during slow joint movement and shock absorption during rapid or high-impact activities.⁴ At a cellular level, HMW-HA interacts with CD44 receptors on chondrocytes and synoviocytes to suppress the production of pro-inflammatory mediators including matrix metalloproteinases (MMP-1, MMP-3, MMP-13), interleukin-1β (IL-1β), tumour necrosis factor-alpha (TNF-α), and nitric oxide (NO).⁴ It also directly influences intra-articular pain receptors, producing analgesic effects through interaction with nociceptor nerve endings.⁴
Low-molecular-weight HA (LMW-HA; <100 kDa) and HA oligosaccharides produced during degradation exhibit different biological properties. While LMW-HA fragments can stimulate pro-inflammatory signalling in some contexts, the oligosaccharides produced by gut microbial degradation of oral HA appear to serve as the absorbed metabolites that deliver systemic benefits.³ Research indicates these fragments are partially absorbed through the intestinal wall and subsequently distributed to joint tissues.⁵
HA synthesis and degradation form a tightly regulated homeostatic cycle. HA is synthesised at the cell surface by three hyaluronan synthase isoenzymes (HAS-1, HAS-2, and HAS-3), which produce polymers of varying molecular weight.⁴ Catabolism occurs via hyaluronidases (primarily HYAL-1 and HYAL-2) and reactive oxygen species. In osteoarthritic joints, this balance shifts toward net degradation — the concentration and average molecular weight of HA decline, compromising the viscosity and lubricating capacity of synovial fluid and accelerating cartilage damage.¹
Health Benefits for Dogs
Joint Lubrication and Viscosupplementation
The most well-established function of HA in joint health is its role as the principal lubricant in synovial fluid. HA provides both boundary lubrication during slow movements and elastohydrodynamic lubrication during rapid joint loading.⁴ In dogs with osteoarthritis, the concentration and molecular weight of synovial fluid HA are significantly reduced. Plickert et al. (2013) demonstrated a significant negative correlation between osteoarthritis severity and synovial fluid HA concentrations in dogs (r = −0.696; p < 0.001), with median HA values declining progressively with increasing disease severity.¹
Oral HA supplementation has been shown to directly counteract this decline. Serra Aguado et al. (2021) conducted a prospective, randomised, double-blind clinical study in 55 dogs with cranial cruciate ligament rupture and found that oral HA administration for 10 weeks produced a significant increase in synovial fluid HA concentration (p = 0.0016) compared to baseline, while the placebo group showed a decline in HA concentration over the same period.²
Anti-Inflammatory Effects
HA exerts anti-inflammatory effects through multiple molecular mechanisms. HMW-HA inhibits the production of matrix metalloproteinases and other cytokine-induced inflammatory mediators, directly suppressing the enzymatic cascade responsible for cartilage breakdown.⁴ In the same canine clinical study by Serra Aguado et al. (2021), oral HA supplementation produced a significant decrease in synovial fluid paraoxonase-1 (PON-1) concentration (p = 0.011) — an oxidative stress biomarker associated with active joint inflammation.²
HA also modulates immune cell activity within the joint capsule. It inhibits the migration of inflammatory cells into the synovial space and reduces synovial hypertrophy while decreasing the number of macrophages, lymphocytes, and mast cells in inflamed joint tissue.⁴
Pain Reduction and Nociceptor Modulation
HA produces analgesic effects through direct interaction with nociceptor nerve endings within the joint.⁴ By interacting with HA receptors on or near free nerve endings, HA attenuates the heightened nerve impulse activity that characterises sensitised joint nociceptors in osteoarthritis.⁴ This mechanism is distinct from the anti-inflammatory pathway and provides an additional route for pain management — HA does not merely reduce the source of pain (inflammation) but also modulates the pain signalling itself.
Cartilage Protection
Beyond lubrication, HA contributes to the structural integrity of articular cartilage. It binds to aggrecan and other proteoglycans within the cartilage matrix, forming large aggregates essential for the tissue’s compressive resistance.⁴ By suppressing MMP activity and reducing oxidative stress within the joint microenvironment, HA helps maintain the balance between cartilage synthesis and degradation that is disrupted in osteoarthritis.
Hyaluronic Acid and Gut Health
The relationship between oral HA and the gut microbiome represents one of the most compelling recent developments in joint-supplement science, and it directly reinforces the gut-joint axis — the bidirectional communication pathway linking intestinal health to joint inflammation and mobility.
Gut-Microbiota-Dependent Absorption
Oral HA cannot be directly absorbed in its intact high-molecular-weight form due to its large size and polyanionic nature. Instead, its bioavailability depends entirely on degradation by gut microbiota. Šimek et al. (2023) demonstrated using ¹³C-labelled hyaluronan that the presence of Bacteroides species in the gut was crucial for HA absorption. These bacteria cleave HA into unsaturated oligosaccharides (<3 kDa), which are then partially absorbed through the intestinal wall. In germ-free mice lacking gut microbiota, HA absorption was virtually absent — confirming that the gut microbiome is the gatekeeper of oral HA bioavailability.³
This has a direct practical implication: the efficacy of oral HA supplementation is influenced by the health and diversity of the gut microbiome. A dog with a well-supported microbiome — including adequate Bacteroides populations — is better positioned to derive benefit from oral HA than one with gut dysbiosis. This is precisely why Bonza formulates Bounce with prebiotic FOS alongside joint-active ingredients: prebiotics support the microbial populations that facilitate HA processing.
HA as a Prebiotic Substrate
Emerging research indicates that HA itself may function as a prebiotic substrate. When degraded by gut bacteria, HA fragments are fermented into short-chain fatty acids (SCFAs) — the same beneficial metabolites produced from dietary fibre that support gut barrier integrity and modulate systemic inflammation.³ Fang et al. (2024) demonstrated that Bacteroides species degrade HA into oligosaccharides that are further fermented through cross-feeding interactions, producing acetate and propionate.⁶
Additionally, Zheng et al. (2021) found that oral HA administration significantly promoted the growth of Akkermansia muciniphila — a keystone species associated with gut barrier integrity and reduced systemic inflammation — and protected against intestinal inflammation in a murine colitis model.⁷ The HA-degrading activity of gut bacteria also increased the abundance of SCFA-producing bacteria including Bifidobacterium and Faecalibacterium species.⁸
The Gut-Joint Axis Connection
The gut-joint axis links intestinal dysbiosis to joint inflammation through several mechanisms, including increased intestinal permeability (allowing bacterial lipopolysaccharides to enter systemic circulation), altered immune regulation, and disrupted SCFA-mediated anti-inflammatory signalling. The dual action of oral HA — supporting beneficial gut bacteria while simultaneously providing absorbable fragments that reach joint tissues — positions it as an ingredient that works through the gut-joint axis rather than merely bypassing it.
For a comprehensive overview of the gut-joint axis and its role in canine joint health, see our dedicated article: The Gut-Joint Axis: How Your Dog’s Gut Health Affects Their Joints.
Why Bonza Includes Hyaluronic Acid
Bonza includes hyaluronic acid at 5mg per chewy in Bounce Bioactive Bites because it addresses a fundamentally different aspect of joint health from the other ingredients in the formulation. While glucosamine HCl (240mg) and chondroitin sulphate (80mg) support cartilage synthesis and structural repair, and anti-inflammatory botanicals like curcumin, Boswellia, and rosehip modulate the inflammatory cascade, HA directly restores the lubrication and viscoelastic properties of synovial fluid — the “oil” that allows joints to move smoothly.
This multi-mechanism approach reflects the complexity of osteoarthritis as a disease. No single ingredient addresses all facets of joint degeneration. Bounce combines structural support (glucosamine, chondroitin, MSM), enzymatic lubrication (hyaluronic acid), anti-inflammatory action (curcumin, Boswellia, algal omega-3), and microbiome support (FOS, β-glucans) into a single daily supplement. The inclusion of prebiotic FOS (80mg) is particularly relevant for HA efficacy, given the gut-microbiota-dependent absorption mechanism described above — by supporting Bacteroides and other beneficial gut bacteria, FOS helps create the microbial environment needed for optimal HA processing and absorption.
HA also complements the ASU (avocado-soybean unsaponifiables, 10mg) in Bounce. Where ASU works primarily at the level of chondrocyte metabolism — stimulating collagen synthesis and inhibiting catabolic enzymes — HA works in the synovial fluid compartment, restoring the physical medium in which the joint operates. Together, they address both the structural tissue (cartilage) and the functional medium (synovial fluid) simultaneously.
Safety Profile
Hyaluronic acid has an excellent safety record in both veterinary and human applications. As a naturally occurring molecule present in every mammalian body, exogenous HA is well tolerated and non-immunogenic.
In the prospective, randomised, double-blind canine clinical study by Serra Aguado et al. (2021) involving 55 dogs receiving oral HA for 10 weeks, no adverse effects attributable to HA supplementation were reported.² This is consistent with the broader veterinary literature — HA has been used therapeutically in dogs, horses, and other species for over four decades with a well-established safety profile.⁴
There are no documented drug interactions specific to oral HA supplementation in dogs. However, as with any supplement intended for dogs with joint conditions, it is advisable to consult a veterinarian before starting supplementation, particularly if the dog is on concurrent NSAID therapy or is recovering from orthopaedic surgery.
HA is not known to be contraindicated in any specific breed, life stage, or health condition when administered orally at supplement-level doses. Dogs with liver disease should be monitored, as serum HA is used as a biomarker for hepatic fibrosis and supplementation could theoretically confound diagnostic interpretation.⁹
How to Give Hyaluronic Acid to Your Dog
How to introduce oral hyaluronic acid supplementation for your dog’s joint health safely and effectively, from veterinary consultation through to ongoing monitoring.
- Consult your veterinarian
Discuss HA supplementation with your vet before starting, particularly if your dog has existing joint conditions, takes NSAIDs, or is recovering from orthopaedic surgery.
- Choose a synergistic formulation
Select an HA supplement that combines it with complementary joint-support ingredients such as glucosamine, chondroitin, prebiotics, and anti-inflammatory botanicals. The gut-microbiota-dependent absorption of HA means formulations including prebiotic support may enhance efficacy.
- Administer daily with food
Give HA consistently with meals. Daily consistency is more important than timing, as HA supplementation builds cumulative benefits over weeks rather than providing immediate relief.
- Allow 8–10 weeks for measurable effect
The canine clinical evidence demonstrates significant biomarker improvements at the 10-week mark.² Joint-support supplements work through gradual physiological mechanisms — expect progressive improvement rather than immediate results.
- Monitor mobility and comfort
Track your dog’s willingness to exercise, ease of rising, stiffness after rest, and overall comfort during daily activities. These functional markers are often the most meaningful indicators of response.
- Review with your veterinarian at 12 weeks
Discuss observed changes with your vet and determine whether to continue, adjust, or complement the supplementation based on your dog’s individual response.
Dosage Guidelines
Hyaluronic acid dosing in the canine clinical literature has used approximately 27mg daily for dogs under 26kg and 54mg daily for dogs over 26kg.² However, these doses were used in a post-surgical context with a high-concentration HA matrix product (Mobilee), and general maintenance supplementation typically uses lower doses.
| Dog Weight | Suggested Daily HA Intake | Bounce Chewies/Day |
|---|---|---|
| Small (up to 10kg) | 2–5mg | 1 chewy |
| Medium (10–25kg) | 5–10mg | 1–2 chewies |
| Large (25–40kg) | 10–15mg | 2–3 chewies |
| Giant (40kg+) | 15–20mg | 3–4 chewies |
Bounce provides 5mg hyaluronic acid per chewy. Follow the dosage guidance on the product label. These guidelines are for general information and do not replace veterinary advice.
Practical Considerations
Onset of effect: HA supplementation is not a fast-acting analgesic. The canine clinical evidence demonstrates significant biomarker improvements at 10 weeks.² Functional improvements in mobility and comfort may emerge gradually over this period. Dog owners should commit to consistent daily supplementation for at least 8–12 weeks before assessing efficacy.
Molecular weight matters: The molecular weight of HA influences both its biological activity and its absorption pathway. High-molecular-weight HA (>500 kDa) provides the strongest anti-inflammatory and viscosupplementation effects but requires gut microbial degradation for oral absorption.³ This is why supporting gut health alongside HA supplementation is beneficial.
Storage and stability: HA is stable in powder and chewy supplement forms at room temperature. Store in a cool, dry place away from direct sunlight and moisture to maintain potency.
Long-term use: There is no evidence of adverse effects from long-term oral HA supplementation. Given that osteoarthritis is a progressive, chronic condition, ongoing supplementation is generally appropriate for dogs with established joint issues or those at increased risk due to breed, size, or age.
Concurrent supplements: HA works synergistically with glucosamine, chondroitin, and omega-3 fatty acids. There are no known negative interactions between oral HA and other common joint supplements. The combined use of multiple joint-support ingredients with complementary mechanisms of action is supported by the veterinary nutraceutical literature.
Frequently Asked Questions
Yes. HA is a naturally occurring molecule present in every dog’s body, concentrated in joints, skin, and eyes. Oral HA supplementation has shown no adverse effects in canine clinical studies, and HA has been used therapeutically in veterinary medicine for over four decades.²˒⁴
Canine clinical research demonstrated significant improvements in joint biomarkers after 10 weeks of daily supplementation.² Functional improvements in mobility and comfort typically emerge gradually over 8–12 weeks. HA is not a fast-acting pain reliever — it works by restoring synovial fluid quality and reducing inflammatory markers over time.
Yes, and this combination is actively recommended. HA and glucosamine address different aspects of joint health — HA restores synovial fluid lubrication while glucosamine supports cartilage synthesis. There are no negative interactions, and the veterinary evidence supports combined use of complementary joint-support ingredients.
Yes. Research has shown that the absorption of oral HA depends on Bacteroides and other gut bacteria that degrade HA into absorbable fragments.³ Supporting gut health with prebiotics and probiotics may enhance the efficacy of oral HA supplementation. This is one of the reasons Bonza Bounce includes prebiotic FOS alongside hyaluronic acid.
Oral and injectable HA work through different mechanisms. Injections deliver HA directly into the joint space for immediate viscosupplementation, while oral HA works systemically through gut-mediated absorption. The canine clinical evidence supports oral HA as an effective complementary approach, particularly for long-term maintenance, but it is not a direct replacement for intra-articular injections in acute or severe cases.²
All sizes of dog can benefit, but large and giant breeds — and dogs predisposed to osteoarthritis through breed-specific conditions like hip dysplasia, elbow dysplasia, or cruciate ligament disease — may benefit most from early and consistent HA supplementation as part of a proactive joint-health strategy.
Related Reading
- The Gut-Joint Axis: How Your Dog’s Gut Health Affects Their Joints
- Avocado-Soybean Unsaponifiables (ASU) for Dogs: Joint Protection & Mobility Support
- Best Prebiotics for Dogs
- The Gut Microbiome: Your Dog’s Hidden Health Command Centre
- Best Probiotics for Dogs: A Canine Nutritionist’s Guide
References
- Plickert HD, Bondzio A, Einspanier R, Tichy A, Brunnberg L. Hyaluronic acid concentrations in synovial fluid of dogs with different stages of osteoarthritis. Research in Veterinary Science. 2013;94(3):728–734. doi: 10.1016/j.rvsc.2012.11.007. PMID: 23261156.
- Serra Aguado CI, Ramos-Plá JJ, Soler C, Segarra S, Moratalla V, Redondo JI. Effects of oral hyaluronic acid administration in dogs following tibial tuberosity advancement surgery for cranial cruciate ligament injury. Animals. 2021;11(5):1264. doi: 10.3390/ani11051264. PMID: 33925642. PMC: PMC8146498.
- Šimek M, Lemke P, Amann R, et al. Molecular weight and gut microbiota determine the bioavailability of orally administered hyaluronic acid. Carbohydrate Polymers. 2023;313:120880. doi: 10.1016/j.carbpol.2023.120880. PMID: 37182970.
- Gupta RC, Lall R, Srivastava A, Sinha A. Hyaluronic acid: molecular mechanisms and therapeutic trajectory. Frontiers in Veterinary Science. 2019;6:192. doi: 10.3389/fvets.2019.00192. PMID: 31294035. PMC: PMC6603175.
- Balogh L, Polyak A, Mathe D, et al. Absorption, uptake and tissue affinity of high-molecular-weight hyaluronan after oral administration in rats and dogs. Journal of Agricultural and Food Chemistry. 2008;56(22):10582–10593. doi: 10.1021/jf8017029. PMID: 18959406.
- Fang Z, Ma M, Wang Y, Dai W, Shang Q, Yu G. Degradation and fermentation of hyaluronic acid by Bacteroides spp. from the human gut microbiota. Carbohydrate Polymers. 2024;334:122074. doi: 10.1016/j.carbpol.2024.122074. PMID: 38553207.
- Mao, T., Su, C. W., Ji, Q., Chen, C. Y., Wang, R., Vijaya Kumar, D., … Shi, H. N. (2021). Hyaluronan-induced alterations of the gut microbiome protects mice against Citrobacter rodentium infection and intestinal inflammation. Gut Microbes, 13(1). doi: 10.1080/19490976.2021.1972757.
- Bosi A, Banfi D, Bistoletti M, et al. Hyaluronan: a neuroimmune modulator in the microbiota-gut axis. Cells. 2021;11(1):126. doi: 10.3390/cells11010126. PMID: 35011688. PMC: PMC8750446.
- Vilar JM, Rubio M, Spinella G, et al. Serum collagen type II cleavage epitope and serum hyaluronic acid as biomarkers for treatment monitoring of dogs with hip osteoarthritis. PLoS ONE. 2016;11(2):e0149472. doi: 10.1371/journal.pone.0149472. PMID: 26886592. PMC: PMC4757546.
Editorial Information
| Field | Detail |
|---|---|
| Published | February 2026 |
| Last Updated | February 2026 — Original publication |
| Reviewed by | Glendon Lloyd, Dip. Canine Nutrition, Dip. Canine Nutrigenomics (Distinction) |
| Next Review | August 2026 |
| Author | Glendon Lloyd |
| Disclaimer | This article is for informational purposes only and does not constitute veterinary advice. Always consult a qualified veterinarian before making changes to your dog’s diet or supplement regimen. |
About the Author
Glendon Lloyd | Dip. Canine Nutrition (Dist.) | Dip. Canine Nutrigenomics (Dist.) Founder, Bonza
Glendon Lloyd is a canine nutrition researcher specialising in nutrigenomics, gut microbiome science, and the therapeutic application of plant-based bioactive compounds. His work focuses on the gut-organ axes and their role in immune function, inflammatory conditions, and healthspan optimisation. He reviews 5–6 peer-reviewed studies weekly to inform evidence-based formulation and clinical guidance.
